CUE (Cue Biopharma) Tax Provision: $0.00 Mil (TTM As of Mar. 2026)


CUE Cue Biopharma Inc CUE
63 GF Score
Price $36.78
GF Value $62.64
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Cue Biopharma Tax Provision?

Cue Biopharma CUE +0.74% 63 Tax Provision is $0.00 Mil as of Mar. 2026. GuruFocus rates CUE with a GF Score™ of 63/100 and a GF Value™ of $62.64 (Possible Value Trap). The stock has 5 warning signs investors should review.

Cue Biopharma's tax provision for the three months ended in Mar. 2026 was $0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Cue Biopharma Tax Provision Historical Data

* Premium members only.

The historical data trend for Cue Biopharma's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cue Biopharma Tax Provision Chart

Cue Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Provision
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.50 0.00 0.00 0.00 -0.50

Cue Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CUE
63GF Score
Cue Biopharma Inc CUE
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cue Biopharma Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of $0.00 Mil mean?
Cue Biopharma (CUE) has a Tax Provision of $0.00 Mil as of Mar. 2026. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Cue Biopharma and its competitors.
Is Cue Biopharma's Tax Provision too high?
Cue Biopharma's current Tax Provision is $0.00 Mil. Overall, Cue Biopharma has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cue Biopharma's Tax Provision compare to ALPS and AARD?
Cue Biopharma's Tax Provision of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Biotechnology company?
A good Tax Provision depends on the Biotechnology industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Cue Biopharma and its competitors. Cue Biopharma's current Tax Provision is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cue Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cue Biopharma (CUE) is currently considered Possible Value Trap. The stock's GF Value™ is $62.64, compared to a current price of $36.78 — trading 41.3% below its estimated fair value. The current Tax Provision is $0.00 Mil. Cue Biopharma's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For Cue Biopharma (CUE), the current Tax Provision is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cue Biopharma (CUE) Overvalued in 2026?

Based on GuruFocus' analysis, Cue Biopharma stock appears to be undervalued. The current stock price of $36.78 is trading 41.3% below its estimated GF Value™ of $62.64. GuruFocus considers Cue Biopharma to be Possible Value Trap.

Key valuation signals for CUE:

  • Tax Provision: $0.00 Mil
  • GF Value™: $62.64 vs. price of $36.78 (41.3% below fair value)
  • GF Score™: 63/100 with 5 warning signs

No single metric tells the full story. See the CUE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cue Biopharma Business Description

Other Exchanges 1UC0:Germany
Address 40 Guest Street, Boston, MA, USA, 02135
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
63GF Score

Get the complete analysis for CUE

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$36.78
Price
$62.64
GF Value